



## Parallel synthesis and anti-inflammatory activity of cyclic peptides cyclosquamosin D and Met-cherimolacyclopeptide B and their analogs

Afef Dellai<sup>a</sup>, Igor Maricic<sup>b</sup>, Vipin Kumar<sup>b</sup>, Sergey Arutyunyan<sup>c</sup>, Abderrahman Bouraoui<sup>a</sup>, Adel Nefzi<sup>c,\*</sup>

<sup>a</sup> Faculté de Pharmacie, Laboratoire de Pharmacologie Marine, 5000 Monastir, Tunisia

<sup>b</sup> Laboratory of Autoimmunity, Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA

<sup>c</sup> Chemistry Department, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, FL 34987, USA

### ARTICLE INFO

#### Article history:

Received 6 May 2010

Revised 4 August 2010

Accepted 6 August 2010

Available online 11 August 2010

#### Keywords:

Parallel synthesis

Solid phase synthesis

Natural cyclopeptides

Anti-inflammatory activity

### ABSTRACT

We report the parallel synthesis of two natural cyclopeptides, isolated from the seeds of *Annona squamosa*, cyclosquamosin D (**A1**), and Met-cherimolacyclopeptide B (**B**) and their analogs. All of the compounds were screened for anti-inflammatory activity by evaluating their inhibitory effects on the production of pro-inflammatory cytokines using the lipopolysaccharide stimulated macrophage J774A.1 cell line. Compounds having significant anti-inflammatory activity in suppressing the secretion of IL-6 and TNF- $\alpha$  have been identified, some of which exhibit activity superior to that observed with the natural products.

© 2010 Elsevier Ltd. All rights reserved.

Cyclic peptides constitute an important group of natural product compounds.<sup>1</sup> Drugs such as vancomycin, cyclosporin, daptomycin, gramicidin S, and bleomycin belong to this group and their successes on the market demonstrate that these types of molecules can be antibiotics and antifungal compounds, as well as immunosuppressive and even anti-cancer drugs.<sup>2</sup> Naturally occurring cyclic peptides continue to hold the attention of synthetic chemists and biologists alike for their intriguing chemical structures and potent biological activities.<sup>3</sup> Cyclic peptides obtained from latex, seeds, and roots of plants possess a wide array of bioactivities including cytotoxic activity,<sup>4,5</sup> immunosuppressive activity,<sup>6</sup> antimalarial activity,<sup>7</sup> vasorelaxant activity,<sup>8</sup> cyclooxygenase, ACE and tyrosinase inhibitory activity,<sup>9,10</sup> and anti-inflammatory activity.<sup>11</sup> Recently, cyclic peptides cyclosquamosin D (**A1**) and cherimolacyclopeptide B have been isolated from seeds of *Annona squamosa* (Fig. 1). The cyclic peptide cyclosquamosin D (**A1**) was reported to have an inhibitory effect on the production of pro-inflammatory cytokines within lipopolysaccharide and Pam3Cys-stimulated J774A.1 macrophages.<sup>11</sup> However, the cyclic peptide cherimolacyclopeptide B was not active in these assays. In this Letter, we report our results on the parallel synthesis of the cyclic peptides cyclosquamosin D (**A1**) and Met-cherimolacyclopeptide B (**B**) and their analogs. All of the synthetically prepared peptides were tested for anti-inflammatory activity.

Using the T-bag technology,<sup>15</sup> the parallel solid phase peptide synthesis<sup>12</sup> of cyclosquamosin D (**A1**) and its 14 analogs (**A2–A15**) was performed starting from Wang-resin bound valine,<sup>13</sup> using Fmoc strategy.<sup>14</sup> As outlined in Scheme 1, all syntheses were performed using standard coupling deprotection cycles in the presence of DIC, HOBT as activating agents and 20% piperidine in DMF for Fmoc deprotection. Following deprotection of the N-terminal protected amino acid, the solid support and all protecting groups were cleaved using HF.

Following extraction, and lyophilization, the identity of the linear peptides were confirmed by LC–MS. The crude peptides were treated overnight in DMF with PyBOP and HOBT in the presence





Figure 1. Natural cyclic peptides: cyclosquamosin D and cherimolacyclopeptide B.

\* Corresponding author. Tel.: +1 772 345 4739; fax: +1 772 345 3649.

E-mail address: [adeln@tpims.org](mailto:adeln@tpims.org) (A. Nefzi).



**Scheme 1.** Parallel synthesis of cyclosquamosin D (**A1**) and its analogs.

of DIEA to generate the corresponding cyclic peptides in good yields.<sup>19</sup> All of the desired compounds were purified using reversed-phase high-performance liquid chromatography (RP HPLC). The purity of these compounds is higher than 90% for all the compounds, based upon analytical traces at  $\lambda = 214$  nm and 254 nm.

In addition to the natural peptide cyclosquamosin D (**A1**), 14 analogs were synthesized. We performed an alanine screen to investigate the effect and contribution of the amino acids Xaa1, Xaa2, Xaa4, Xaa6, and Xaa7 on the anti-inflammatory activity (Table 1). Thus, five cyclic peptide analogs (**A9**, **A11–A13**, and **A15**) were synthesized. We also performed the synthesis of cyclic peptide analogs where we modified or permuted the order of some amino acids. In analog **A4**, the tyrosine at position R<sup>4</sup> and the serine at position R<sup>6</sup> were reversed, while in analog **A8**, the glycine at R<sup>1</sup> was replaced with tyrosine and the order of amino acids at R<sup>2</sup> and R<sup>3</sup> was reversed. In analog **A14**, the proline and glycine at positions R<sup>2</sup> and R<sup>3</sup> were reversed. We also addressed the amino acids bearing functional groups on their side chains. Thus, in analog **A2**, the serine at position 6 was replaced by the threonine and in analog


**A3**, the tyrosine at position R<sup>4</sup> and the serine at R<sup>6</sup> were both substituted by the threonine. In analogs **A5** and **A10**, we addressed the importance of tyrosine at position R<sup>4</sup> by replacing it with serine and *O*-methyl tyrosine. We also addressed the importance of having glycine at position R<sup>1</sup> and R<sup>2</sup> by replacing them with tyrosine in analogs **A6** and **A7**, respectively.

Similarly, we performed the parallel solid phase synthesis<sup>15</sup> of 13 analogs of cherimolacyclopeptide B (**B**). In comparison to the natural cyclic peptide we used the methionine instead of the sulfide methionine (**B1–B13**). As outlined in Scheme 2, the parallel synthesis was performed using Fmoc-chemistry.

Since the natural cyclic peptide cherimolacyclopeptide B (**B**) contains glutamine, the methionine containing analogs of cherimolacyclopeptide B were synthesized using amino acid side chain attachment strategy.<sup>16</sup> Thus, starting from *p*-methylbenzhydrylamine hydrochloride (MBHA-HCl) resin, and following neutralization of the resin, Fmoc-Glu-O<sup>t</sup>Bu was attached to the solid support in the presence of DIC and HOBT. Following Fmoc deprotection, and subsequent coupling of the amino acids using standard

**Table 1**  
Amino acids sequences of the cyclic cyclosquamosin D (**A1**) and its analogs

		Xaa1	Xaa2	Xaa3	Xaa4	Xaa5	Xaa6	Xaa7
Cyclosquamosin D ( <b>A1</b> )	Val	Gly	Gly	Pro	Tyr	Tyr	Ser	Leu
<b>A2</b>	Val	Gly	Gly	Pro	Tyr	Tyr	<b>Thr</b>	Leu
<b>A3</b>	Val	Gly	Gly	Pro	<b>Thr</b>	Tyr	<b>Thr</b>	Leu
<b>A4</b>	Val	Gly	Gly	Pro	<b>Ser</b>	Tyr	<b>Tyr</b>	Leu
<b>A5</b>	Val	Gly	Gly	Pro	<b>Ser</b>	Tyr	Ser	Leu
<b>A6</b>	Val	<b>Tyr</b>	Gly	Pro	Tyr	Tyr	Ser	Leu
<b>A7</b>	Val	Gly	<b>Tyr</b>	Pro	Tyr	Tyr	Ser	Leu
<b>A8</b>	Val	<b>Tyr</b>	<b>Pro</b>	<b>Gly</b>	Tyr	Tyr	Ser	Leu
<b>A9</b>	Val	Gly	Gly	Pro	Tyr	Tyr	Ser	<b>Ala</b>
<b>A10</b>	Val	Gly	Gly	Pro	<b>Tyr(OMe)</b>	Tyr	Ser	Leu
<b>A11</b>	Val	<b>Ala</b>	Gly	Pro	Tyr	Tyr	Ser	Leu
<b>A12</b>	Val	Gly	<b>Ala</b>	Pro	Tyr	Tyr	Ser	Leu
<b>A13</b>	Val	Gly	Gly	Pro	<b>Ala</b>	Tyr	Ser	Leu
<b>A14</b>	Val	Gly	<b>Pro</b>	<b>Gly</b>	Tyr	Tyr	Ser	Leu
<b>A14</b>	Val	Gly	Gly	Pro	Tyr	Tyr	<b>Ala</b>	Leu



**Scheme 2.** Parallel synthesis of Met-cherimolacyclopeptide B (**B1**) and its analogs.

stepwise Fmoc chemistry, the N-terminal amine was deprotected and the *tert*-butyl group on the C $^{\alpha}$  of the glutamic acid was removed with a solution of TFA in DCM. The resin-bound linear peptide was treated with HBTU to generate the corresponding cyclic compounds. The desired cyclic peptides were obtained following cleavage of the solid support with HF/anisole. All the compounds were purified using RP HPLC. The purity of these compounds is higher than 90% for all the compounds, based upon the analytical traces at  $\lambda = 214$  nm and 254 nm.

We performed the synthesis of the methionine analog **B1** of the cyclic natural peptide cherimolacyclopeptide B. We used an alanine substitution screen to study the effect and contribution of each amino acid to the activity (**B2–B8**). In addition, we synthesized five cherimolacyclopeptide B analogs, where we substituted the threonine at position R $^7$  by different amino acids bearing the hydroxyl group on the side chain (Ser, Tyr, D-Thr, D-Ser, and D-Tyr) (**B9–B13**) (Table 2).

**Cell culture:** Murine macrophage J774A.1 cells were purchased from the ATCC and cultured in the RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (Hyclone), L-glutamine, penicillin–streptomycin, sodium pyruvate, non-essential amino acids, HEPES, and 2-mercaptoethanol. For stimulation assays, J774A.1 cells were incubated at 37 °C with the cyclic peptides for 1 h, followed by lipopolysaccharide (LPS) (0.1  $\mu$ g/mL) treatment for additional 4 or 6 h. Cyclic peptides were dissolved in dimethyl sulfoxide, DMSO at concentration of 20–40  $\mu$ g/mL.


**Enzyme-linked immunosorbent assay (ELISA):** Anti-mouse IL-6 and TNF- $\alpha$  antibodies as well as recombinant mouse IL-6 and TNF- $\alpha$  for ELISA standards were purchased from eBioscience (San

**Table 2**

Amino acids sequences of Met-cherimolacyclopeptide B (**B1**) and its analogs

		Xaa1	Xaa2	Xaa3	Xaa4	Xaa5	Xaa6	Xaa7
<b>B1</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	Thr
<b>B2</b>	Fmoc-Glu-O- <sup>t</sup> Bu	<b>Ala</b>	Ile	Pro	Leu	Met	Gly	Thr
<b>B3</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	<b>Ala</b>	Pro	Leu	Met	Gly	Thr
<b>B4</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	<b>Ala</b>	Leu	Met	Gly	Thr
<b>B5</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	<b>Ala</b>	Met	Gly	Thr
<b>B6</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	<b>Ala</b>	Gly	Thr
<b>B7</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	<b>Ala</b>	Thr
<b>B8</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>Ala</b>
<b>B9</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>Ser</b>
<b>B10</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>Tyr</b>
<b>B11</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>D-Tyr</b>
<b>B12</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>D-Thr</b>
<b>B13</b>	Fmoc-Glu-O- <sup>t</sup> Bu	Pro	Ile	Pro	Leu	Met	Gly	<b>D-Ser</b>

Diego). Avidin-HRP peroxidase was purchased from Vector Laboratories and ABTS peroxidase substrate system from KPL.



**Figure 2.** Inhibitory effect of cyclic peptides on the production of TNF- $\alpha$  and IL-6 by LPS-stimulated J774A.1 cells. IL-6 secretion after 4 h of LPS treatment (upper panel). Values are mean  $\pm$  SD, \*:  $p$  value for **A10**, **A11**, **A12**, **B6**, **B7** is  $<0.0001$ . TNF- $\alpha$  secretion after 4 h of LPS treatment (lower panel). Values are mean  $\pm$  SD, \*:  $p$  values for **A12**, **B6**, and **B7** are 0.0137, 0.0005, and 0.0268, respectively. These data are representative of three independent experiments.

The cytokine Elisa was performed essentially as described earlier.<sup>17,18</sup> Anti-IL-6 or anti-TNF- $\alpha$  capture antibodies were diluted to 1  $\mu$ g/mL in PBS. Fifty microliters of diluted antibody was added to the wells of Nunc Maxisorp plate. Plates were then incubated overnight at 4  $^{\circ}$ C. The next day they were washed 2 $\times$  with PBS/


Tween solution (0.05%) and then blocked with 200  $\mu$ L of blocking buffer (10% FBS in PBS solution) and incubated at room temperature for 2 h. Following washing four to five times with PBS/Tween, IL-6, or TNF- $\alpha$  standards and samples were added (50  $\mu$ L/well). Plates were sealed overnight at 4  $^{\circ}$ C and washed next day five times with PBS/Tween solution. The biotinylated anti-IL-6 or anti-TNF- $\alpha$  detection antibodies were diluted to 1 mg/mL in PBS and added at 100  $\mu$ L/well. Plates were incubated for 1 h at room temperature and then washed six times with PBS/Tween. Avidin-HRP peroxidase conjugate was diluted to 2.5 mg/mL in PBS and added 100  $\mu$ L/well and plates were incubated at room temperature for 30 min. After washing six times with PBS/Tween, ABTS substrate solution, and peroxidase substrate solutions were mixed at 1:1 ratio and added at 100  $\mu$ L/well and plates covered with aluminum foil. After 10–20 min the optical density was read at 405 nm using a microplate reader.

Infections with pathogenic agents, including viruses and bacteria can result in overproduction of pro-inflammatory cytokines, including IL-6 and TNF- $\alpha$ . We have determined whether treatment with synthetic cyclic peptides has any influence on the secretion of these cytokines by a murine macrophage cell line, J 774A.1 cells. These cells were pre-treated with various synthetic cyclic peptides for 1 h at 37  $^{\circ}$ C. Following treatment with peptides, cells were stimulated for 6 h with LPS, a gram-negative bacterial cell wall component. LPS has been shown to induce signaling for the production of cytokines via toll-like receptor 4.


**Screening results:** All the synthetic cyclic peptides were examined for their ability to block IL-6 or TNF- $\alpha$  using the J774A.1 cell line. A wide array of biological activity was observed among the analogs with some exhibiting no activity with others exhibiting activity superior to the natural products. Some analogs of both A and B peptides that were found to show suppression of inflammatory responses in bulk assays were further examined along with some that showed no activity which were included as negative controls. As shown in Figure 2, while **A10**, **A11**, and **A12** significantly reduced IL-6 secretion, only **A12** was able to block TNF- $\alpha$  secretion as well. It is interesting that, although **A10** was most effective (up to ~25%) in suppressing IL-6, it had no effect on the secretion of TNF- $\alpha$ .

Similar to what was reported for the natural cyclic peptide cherimolacyclopeptide B, the Met-cherimolacyclopeptide B (**B1**) did not show activity. In contrast, both analogs of Met-cherimolacyclopeptide B (**B1**), cyclic peptides **B6** and **B7** were able to effectively suppress TNF- $\alpha$  and IL-6 secretion. Whereas, peptide analog **B10** showed no activity in reducing LPS-induced cytokine secretion by macrophages and served as a negative control.

Structurally, these peptide analogs are very similar and yet they generate specific anti-inflammatory activity. The methylation of the hydroxyl group of the tyrosine (R<sup>4</sup>) in analog **A10** significantly reduced IL-6 secretion. Similarly, the substitution of the glycine



**Figure 3.** Structures of the individual analogs of cyclosquamosin D showing an inhibitory effect on the production of pro-inflammatory cytokines within lipopolysaccharide stimulated J774A.1 macrophages.



**Figure 4.** Structures of the individual analogs of cherimolacyclopeptide B showing an inhibitory effect on the production of pro-inflammatory cytokines within lipopolysaccharide stimulated J774A.1 macrophages.

(R<sup>1</sup>) and the glycine (R<sup>2</sup>) by alanine for analogs **A11** and **A12**, respectively, resulted in reduction of IL-6 secretion (Fig. 3).

Interesting results were obtained for cyclic peptides Met-cherimolacyclopeptide B analogs. The substitution of methionine (R<sup>5</sup>) and Gly (R<sup>6</sup>) by alanine for analogs **B6** and **B7** (Fig. 4), respectively, resulted in suppression of TNF- $\alpha$  and IL-6 secretion.

In summary, we performed the parallel synthesis of two natural cyclopeptides and their analogs. We tested all the compounds for anti-inflammatory activity for their inhibitory effect on the production of pro-inflammatory cytokines using lipopolysaccharide stimulated J774A.1 macrophage line. Modified analog compounds of cyclosquamosin D (**A1**) showed significant anti-inflammatory activity in suppressing the secretion of IL-6 and TNF- $\alpha$ , in some cases superior to the activity observed with the natural product. Similarly, we were able to identify active compounds analogs of the non-active natural cyclic peptide cherimolacyclopeptide B.

## Acknowledgment

The presented work was supported by Grants from the NIH, JDRF, and MSNRC (V.K.). NIH (1R03DA025850-01A1, Nefzi), NIH (5P41GM081261-03, Houghten), and NIH (3P41GM079590-03S1,

Houghten), the State of Florida Funding and the Tunisian Ministry of Higher Education.

## References and notes

- (a) Tamai, S.; Kaneda, M.; Nakamura, S. *J. Antibiot.* **1982**, *35*, 1130; (b) Walsh, C. T. *Science* **1993**, *261*, 308; (c) Kannan, R.; Harris, C. M.; Harris, T. M.; Waltho, G. P.; Skelton, N. J.; Williams, D. H. *J. Am. Chem. Soc.* **1988**, *110*, 2946.
- (a) Wipf, P. *Chem. Rev.* **1995**, *95*, 2115; (b) Hamada, Y.; Shioiri, T. *Chem. Rev.* **2005**, *105*, 4441; (c) Pomilio, A. B.; Battista, M. E.; Vitale, A. A. *Curr. Org. Chem.* **2006**, *10*, 2075.
- Blout, E. R. *Biopolymers* **1981**, *20*, 1901.
- Mongkolvisut, W.; Sutthivaiyakit, S.; Leutbecher, H.; Mika, S.; Klaiber, I.; Moller, W.; Rosner, H.; Beifuss, U.; Conrad, J. *J. Nat. Prod.* **2006**, *69*, 14355.
- Dahiya, R.; Kaur, K. *Arch. Pharm. Res.* **2007**, *30*, 1380.
- Morita, H.; Shishido, A.; Matsumoto, T.; Itokawa, H.; Takeya, K. *Tetrahedron* **1999**, *55*, 967.
- Baraguey, C.; Blond, A.; Correia, I.; Pousset, J.-L.; Bodo, B.; Auvin-Guette, J.-L.; Mahafacyclin, A. *Tetrahedron Lett.* **2000**, *41*, 325.
- Morita, H.; Lizuka, T.; Choo, C. Y.; Chan, K. L.; Itokawa, H.; Takeya, K. *J. Nat. Prod.* **2005**, *68*, 1686.
- Morita, H.; Shishido, A.; Kayashita, T.; Takeya, K.; Itokawa, H. *J. Nat. Prod.* **1997**, *60*, 404.
- Yahara, S.; Shigeyama, C.; Nohara, T.; Okuda, H.; Wakamatsu, K.; Yasuhara, T. *Tetrahedron Lett.* **1989**, *30*, 6041.
- Yang, Y. L.; Hua, K. F.; Chuang, P. H.; Wu, S. H.; Wu, K. Y.; Chang, F. R.; Wu, Y. C. *J. Agric. Food Chem.* **2008**, *56*, 386.
- (a) Merrifield, R. B. *J. Am. Chem. Soc.* **1963**, *85*, 2149; (b) Merrifield, R. B. *Science* **1966**, *232*, 341.
- Mitchell, A. R. *Biopolymers* **2008**, *90*, 3175.
- Fields, G. B.; Noble, R. L. *Int. J. Pept. Protein Res.* **1990**, *35*, 161.
- Houghten, R. A. *Proc. Natl. Acad. Sci. U.S.A.* **1985**, *82*, 5131.
- (a) Cabrele, C.; Langer, M.; Beck-Sickinger, A. G. *J. Org. Chem.* **1999**, *64*, 4353; (b) Ficht, S.; Payne, R. J.; Guy, R. T.; Wong, C.-H. *Chem.-A Eur. J.* **2008**, *14*, 3620; (c) Dixon, M. J.; Nathubhai, A.; Andersen, O. A.; van Aalten, D. M. F.; Eggleston, I. M. *Org. Biomol. Chem.* **2009**, *7*, 259.
- Tang, X.; Maricic, I.; Purohit, N.; Bakamjian, B.; Reed-Loisel, L. M.; Beeston, T.; Jensen, P.; Kumar, V. J. *Immunol.* **2006**, *177*, 7645.
- Smith, T. R.; Tang, X.; Maricic, I.; Garcia, Z.; Fanchiang, S.; Kumar, V. J. *Immunol.* **2009**, *182*, 6959.
- 10 mg of linear crude peptide was dissolved in 600  $\mu$ L of DMF anhydrous. PyBOP (3 equiv) and HOBt (3 equiv) were added to the reaction vessel in the presence of DIEA (3 equiv). The clear solution was stirred overnight at room temperature. The completion of the cyclization was monitored by LC-MS. The DMF was evaporated and the crude product was purified using reversed-phase high-performance liquid chromatography (RP HPLC). All the compounds were obtained in good yield ranging from 50 to 60%.